The term bispecific antibody (bsAb) is used to describe a large family of molecules designed
to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from …

T cell-based immunotherapies have revolutionized treatment paradigms in various cancers,
however, limited response rates secondary to lack of significant T-cell infiltration in the tumor …

Patients with B-lineage acute lymphoblastic leukemia (ALL) are at high-risk for relapse after
allogeneic hematopoietic cell transplantation (HCT). We conducted a single-center phase 2 …

Despite improved outcomes achieved in the last decades for children with newly diagnosed
leukaemia and lymphoma, treatment of patients with refractory/relapsed disease remains a …

Simple Summary Bispecific T-cell engagers (BiTEs) and bispecific antibodies (BiAbs) have
emerged as novel therapeutic modalities in the treatment of advanced hematological …

Highlights•Immune cell engagers (ICEs) are molecules able to redirect immune effector cells
against cancer cells.•ICEs can be used for the redirection of T cells, natural killer (NK) cells …

The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell
precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® …

Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in
relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for …

Patients with acute lymphoblastic leukemia have experienced significantly improved
outcomes due to the advent of chimeric antigen receptor (CAR) T cells and bispecific T-cell …

T-cell bispecific antibodies (T-BsAbs) such as blinatumomab hold great promise for cancer
immunotherapy. A better understanding of the in vivo immune response induced by T-BsAbs …